Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol  March 11, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors.  Further, the Company announced that it […]